In vitro and In Silico Studies on Curcumin and Its Analogues as Dual Inhibitors for cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2)


  • Nunung Yuniarti 1Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia
  • Perdana Adhi Nugroho 2Curcumin Research Centre, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia
  • Aditya Asyhar 2Curcumin Research Centre, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia
  • Sardjiman Sardjiman 3Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia
  • Zullies Ikawati 1Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia
  • Enade Perdana Istyastono 4Leiden/Amsterdam Center for Drug Research (LACDR), Division of Medicinal Chemistry, Department of Pharmacochemistry, Faculty of Exact Sciences, Vrije University Amsterdam, De Boelelaan 1083, 1081 HV Amsterdam, The Netherlands



Curcumin has been widely reported as an anti-inflammatory agent isolated from the plant Curcuma longa L. (turmeric). This anti-inflammatory activity was associated with the ability of this compound to inhibit the activity of both cyclooxygenase-1(COX-1) and cyclooxygenase-2(COX-2) in arachidonic acid metabolism. Dual COX-1 and COX-2 inhibitors are preferred to be employed in the therapy of chronic inflammatory diseases compared to selective inhibitors, since it was reported that the use of selective inhibitors led to severe adverse side effect. In the present study, in vitro and in silico assays on curcuminand its analogues as dual inhibitors for both COX-1 and COX-2 were performed. The results provide theoretical contribution in understanding the ligand-protein interactions at the molecular level to develop new curcumin analogues which possess better anti-inflammatory activity as well as to avoid unsolicited side effects.


Joe, B., Vijaykumar, M., & Lokesh, B.R., Biological Properties of Curcumin-Cellular and Molecular Mechanisms of Action, Crit. Rev. Food Sci. Nutr., 44, pp. 97-111, 2004.

Sharma, R.A., Gescher, A.J., & Steward, W.P., Curcumin: The Story So Far, Eur. J. Cancer, 41, pp. 1955-1968, 2005.

Handler, N., Jaeger, W., Puschacher, H., Leisser, K., & Erker, T., Synthesis of Novel Curcumin Analogues and Their Evaluation as Selective Cyclooxygenase-1 (COX-1) Inhibitors, Chem. Pharm. Bull., 55, pp. 64-71, 2007.

Hong, J., Bose, M., Ju, J., Ryu, J.H., Chen, X., Sang, S., Lee, M.J., & Yang, C.S., Modulation of Arachidonic Acid Metabolism by Curcumin and Related Y-Diketone Derivatives: Effects on Cytosolic Phospholipase A2, Cyclooxygenases and 5-Lipoxygenase, Carcinogenesis, 25, pp. 1671-1679, 2004.

Weber, W.M., Hunsaker, L.A., Roybal, C.N., Bobrovnikova-Marjon, E.V., Abcouwer, S.F., Royer, R.E., Deck, L.M., & Vander Jagt D. L., Activation of NFB is Inhibited by Curcumin and Related Enones, Bioorg. Med. Chem., 14, pp. 2450-2461, 2006.

Woo H. B., Shin W. S., Lee S., & Ahn C. M., Synthesis of Novel Curcumin Mimics With Asymmetrical Units And Their Anti-Angiogenic Activity, Bioorg. Med. Chem. Lett., 15, 3782-3786, 2005.

Zhang F., Altorki N. K., Mestre J. R., Subbaramaiah K., & Dannenberg A. J., Curcumin Inhibits Cyclooxygenase-2 Transcription in Bile Acid- and Phorbol Ester-Treated Human Gastrointestinal Epithelial Cells, Carcinogenesis, 20, pp. 445-451, 1999.

Zambre, A.P., Ganure, A.L., Shinde, D.B., & Kulkarni, V.M., Perspective Assessment of COX-1 and COX-2 Selectivity of Nonsteroidal Anti-Inflammatory Drugs from Clinical Practice: Use of Genetic Function Approximation, J. Chem. Inf. Model., 47, pp. 635-643, 2007.

Dvory-Sobol, H. & Arber, N., Cyclooxygenase-2 as Target for Chemopreventive Interventions: New Approaches, Cancer Biomarkers, 3 (3), pp. 153-161, 2007.

van Ryn, J. & Pairet, M., Selective Cyclooxygenase-2 Inhihitors: Pharmacology, Clinical Effects And Therapeutic Potential, Expert Opin. Investig. Drugs, 6, pp. 609-614, 1997.

Gilroy, D.W., Tomlinson, A., & Willoughby, D.A., Differential Effects of Inhibition of Isoforms of Cyclooxygenase (COX-1, COX-2) in Chronic Inflammation, Inflamm. Res., 47, pp. 79-85, 1998.

Saw, C.L., Huang,Y.I., & Cong, A.N., Synergistic Anti-Inflammatory Effects of Low Doses of Curcumin in Combination with Polyunsaturated Fatty Acids: Docosahexaenoic Acid or Eicosapentaenoic Acid, Biochem. Pharmacol., 2009.

Padhye, S., Banerjee, S., Chavan, D., Pandye, S., Swamy, K.V., Ali, S., Li, J., Dou, Q.P., & Sarkar, F.H., Fluorocurcumins as Cyclooxygenase-2 Inhibitor: Molecular Docking, Pharmacokinetics and Tissue Distribution in Mice, Pharm. Res., 26, pp. 2438-2445, 2009.

Kapetanovic, I.M., Computer-Aided Drug Discovery and Development (CADDD): in Silico-Chemico-Biological Approach, Chem. Biol. Interact., 171, pp. 165-176, 2008.

van Gisteren, W.F., Bakowies, D., Baron, R., Chandrasekhar, I., Christen, M., Daura, X., Gee, P., Geerke, D.P., Glattli, A., Hunenberger, P.H., Kastenholz, M.A., Oostenbrink, C., Schenk, M., Trzesniak, D., van der Vegt, N.F., & Yu, H.B., Biomolecular Modeling: Goals, Problems, Perspectives, Angew. Chem. Int. Ed. Engl., 45, 4064-4092, 2006.

Appiah-Opong, R., Commandeur, J.N., Istyastono, E., Bogaards, J.J., & Vermeulen, N.P., Inhibition of Human Glutathione S-Transferases by Curcumin and Analogues, Xenobiotica, 39, pp. 302-311, 2009.

Fujisawa, S., Ishihara, M., Murakami, Y., Atsumi, T., Kadoma, Y. & Yokoe, I., Predicting the Biological Activities of 2-Methoxyphenol Antioxidants: Effects of Dimers, In Vivo, 21, pp. 181-188, 2007.

Reksohadiprojo, M.S., Timmerman, H., Sardjiman, Margono, S.A., Martono, S., Sugiyanto, Hakim, L., Nurlaila, Hakim, A.R., Puspitasari, I., Nurrochmad, A., Purwantiningsih, Oetari, & Tedjo, Y., Derivatives of Benzylidene Cyclohexanone, Benzylidene Cyclopentanone, and Benzylidene Acetone, and Therapeutic Uses Thereof, United States Patent Application Publication No.: US2003092772, 2003.

Sardjiman, Reksohadiprodjo, M.S., Hakim, L., van der Goot, H., & Timmerman, H., 1,5-Diphenyl-1,4-Pentadiene-3-Ones and Cyclic Analogues as Antioxidative Agents. Synthesis and Structure-Activity Relationship, Eur. J. Med. Chem., 32, pp. 625-630, 1997.

Yang, M.H., Yoon, K.D., Chin, Y.W., Park, J.H., & Kim, J., Phenolic Compounds with Radical Scavenging and Cyclooxygenase-2 (COX-2) Inhibitory Activities from Dioscorea Opposite, Bioorg. Med. Chem., 17, pp. 2689-2694, 2009.

Marcou, G. & Rognan, D., Optimizing Fragment and Scaffold Docking by Use of Molecular Interaction Fingerprints, J. Chem. Inf. Model., 47, pp. 195-207, 2007.

OpenEye Scientific Software, Inc., Santa Fe, NM, USA,

Kurumbail, R.G., Stevens, A.M., Giese, J.K., McDonald, J.J., Stegeman, R.A., Pak, J.Y., Gildehaus, D., Miyashiro, J.M., Penning, T.D., Seibert, K., Isakson, P.C., & Stallings, W.C., Structural Basis for Selective Inhibition Of Cyclooxygenase-2 by Anti-Inflammatory Agents, Nature, 384, pp. 644-648, 1996.

Selinsky, B.S., Gupta, K., Sharkey, C.T., & Loll, P.J., Structural Analysis of NSAID Binding by Prostaglandin H2 Synthase: Time-Dependent and Time-Independent Inhibitors Elicit Identical Enzyme Conformations, Biochemistry, 40, pp. 5172-5180, 2001.

Larkin, M.A., Blackshields, G., Brown, N.P., Chenna, R., McGettigan, P.A., McWilliam, H., Valentin, F., Wallace, I.M., Wilm, A., Lopez, R., Thompson, J.D., Gibson, T.J., & Higgins, D.G., Clustal W and Clustal X version 2.0., Bioinformatics, 23, pp. 2947-2948, 2007.

de Graaf, C. & Rognan, D., Selective Structure-Based Virtual Screening for Full and Partial Agonists of the 2 Adrenergic Receptor, J. Med. Chem., 51(16), pp. 4978-4985, 2008.